Bluejay Therapeutics expands management team and hired

SAN MATEO, Calif., Sept. 21, 2023 (World NEWSWIRE) — Bluejay Therapeutics, Inc. a non-public clinical phase biopharmaceutical firm concentrated on viral and liver disorders, currently declared the appointment of Christopher Holterhoff as Senior Vice President, Head of Company Enhancement. Mr. Holterhoff will direct Bluejay’s business enterprise and corporate enhancement purpose and will play a considerable position in Bluejay’s corporate method and strategic setting up functions. He will be a member of Bluejay’s Executive staff, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.

“I am delighted to welcome Chris to the senior management staff at Bluejay”, stated Mrs. Chu. “Chris has an exceptional observe record in business enterprise & company growth with each general public and personal biotech and pharma providers. His business improvement encounter, as nicely as his strategic aptitude will engage in a vital part as we execute on our vision of developing a foremost biotechnology company centered on healing treatment options for severe viral and liver diseases.”

“Bluejay is really very well-positioned with a pipeline of initial-in-class or most effective-in-class remedy alternatives addressing serious and remarkably commonplace viral and liver health conditions in which there exists substantial unmet health care want. I am thrilled to be a part of the group at these kinds of a pivotal time in its improvement, and I look forward to operating with Bluejay’s outstanding staff and leveraging my practical experience in company advancement to progress the company’s promising pipeline toward acceptance for clients who are in dire need of new procedure options.”

Mr. Holterhoff has approximately two decades of numerous encounter encompassing business enterprise & company progress, corporate finance & tactic, and funds marketplaces.

Before signing up for Bluejay, he served as VP, Enterprise & Corporate enhancement at LEXEO Therapeutics, where he led all company development, strategic transactions and played a major role in the company’s money raising activities. Prior to LEXEO, Mr. Holterhoff served as government director of business enterprise improvement at Amicus Therapeutics wherever he executed on new strategic company opportunities for Amicus’ gene remedy pipeline, which include license agreements, M&A transactions, and R&D collaborations, and led the alliance management perform. Earlier in his vocation, he labored in healthcare investment decision banking at MTS Wellness Associates, in which he recommended public and non-public biotechnology and pharmaceutical companies on strategic get and offer facet transactions and financings and served as a senior publishing fairness research analyst at Oppenheimer & Co. Inc., offering coverage of biotechnology and pharmaceutical organizations.

Mr. Holterhoff holds an MBA from Columbia College, MS in Biotechnology from Georgetown College, and BS from Providence Higher education.

Mr. Holterhoff joins a seasoned executive management team, together with:

Keting Chu, M.D., Ph.D., founder and chief govt officer, was beforehand a companion at LYFE Cash and enterprise partner at Apple Tree Associates, and was dependable for undertaking philanthropy at The Leukemia and Lymphoma Culture. Dr. Chu was also the CEO of quite a few companies, including Mission Therapeutics, DigitAB, and BioCubed Corporation. Previously in her vocation, she held R&D leadership roles at 5 Primary Therapeutics and Chiron Company.

Hassan Javanbakht, Ph.D., chief scientific officer, was previously at Hoffman La-Roche, Gilead sciences and SQZ biotechnologies the place he labored on developing novel antivirals and immunomodulators to address HIV, HBV, influenza and other infectious disorders. He was portion of the crew that highly developed Elipida® (RO4970335), a potent and remarkably selective NNRTI, into clinical enhancement . He led the groups that designed a to start with-in-class small-molecule viral expression inhibitor (RG7834) and a liver-qualified anti-HBV locked nucleic acid (RG6004). His operate also led to discovery of PAPD5/7 as host elements for HBV expression. He has authored additional than 45 peer-reviewed scientific publications in substantial-effects journals and retains a lot more than 11 issued patents and programs.

Nancy Shulman, M.D., CMO, has in excess of 20 years of medical development knowledge together with at Roche, Genentech, AbbVie, and most not long ago at Ambys Medications, where she was the vice president of translational medication. She delivers wide clinical development knowledge ranging from to start with-in-human and translational scientific tests by way of Phase 4 reports, including substantial working experience in the virology/hepatology condition place, but also in immunology and oncology. She has been a component of a number of INDs and was a important leader on the NDA approvals of the HCV antivirals Viekira Pak®, Viekirax®, and Mavyret®.

Kevin Lin, M.D., vice president of growth, has above 30 yrs of practical experience in the biotechnology business in the regions of procedure improvement, technology transfer, scale up, troubleshooting, GMP producing, and CMC regulatory submission. He has labored at several biotech companies, these kinds of as Bayer Health care, Catalant, Avid Bioservices, ImmunityBio, and Kindred Biosciences.

Jeff Zablocki, Ph.D., vice president of chemistry, has led chemistry groups at AbbVie, Gilead, CV Therapeutics, Amgen, and Searle. Dr. Zablocki has found out 15 progress compounds together with 3 approved agents: Lexiscan™ – an adenosine A2A agonist used in over 60 million people as a pharmacological strain agent capturing a large market share Ranexa™ for steady angina and Voxilaprevir™ for Hepatitis C in which he helped address pre-medical metabolism worries by implementing novel medicinal chemistry methods.

About Bluejay Therapeutics

Bluejay Therapeutics is a clinical phase personal biopharmaceutical business committed to creating successful remedies and cures for viral and liver ailments ( Its first goal indications are CHB and CHD, illnesses that have a world-wide prevalence and an urgent have to have for enhanced health care solutions. Bluejay is advancing two likely therapeutic ways: ideal-in-class thoroughly human IgG1 anti-HBs monoclonal antibodies and orally liver-targeted HBV transcript inhibitors. The business has formulated a system for liver-directed drug focusing on, with probable purposes to numerous therapeutic agents. For extra info on potential collaborations with Bluejay Therapeutics relating to partnering alternatives or preclinical or scientific exploration packages, please make contact with us at [email protected].

Related posts